Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal — Update
Regeneron Pharmaceuticals Inc RGO
News
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Regeneron Posts Higher 2Q Revenue, Sees Improving Profit
Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis
U.S. plans to move physicians exposed to rare Ebola virus to Germany
Health officials declare Ebola outbreak a public health emergency
Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU
Regeneron Gets FDA OK for Extended Eylea HD Dosing
Regeneron, Sanofi Get CHMP Backing for Dupixent in Younger Children With CSU
Regeneron, Sanofi Get FDA Approval For Dupixent in Allergic Fungal Rhinosinusitis
Regeneron Gets Speedy FDA Review of Garetosmab in FOP
TrumpRx is here. This is why it won't lower drug prices for most Americans.
Pharma stocks advance as Trump rolls out drug-pricing deals with 9 more companies
Regeneron, Sanofi Get EU Approval For Dupixent in Skin Disease CSU — Update
Regeneron, Sanofi Get EU Approval For Dupixent in Skin Disease CSU
Regeneron Gets FDA Approval for Eye Treatment Eylea
Sanofi, Regeneron's Dupixent Hits Key Goals in Late-Stage Fungal Allergy Trial
Regeneron Sees $83 Million Charge Hurting 3Q Results
Regeneron: FDA Expands Evkeeza Approval to Children as Young as 1
Sanofi Sees Progress for Hives Treatment in EU, Longer U.S. Review for MS Drug
United States